Rapport Therapeutics
RAPP
35 hedge funds and large institutions have $593M invested in Rapport Therapeutics in 2024 Q2 according to their latest regulatory filings, with 35 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
74.47% more ownership
Funds ownership: 0% → 74.47% (+74%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$115M |
| 2 |
AVM
Arch Venture Management
Chicago,
Illinois
|
+$86.3M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$68.1M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$60.3M |
| 5 |
JJ
Johnson & Johnson
New Brunswick,
New Jersey
|
+$57.8M |
Top Sellers
RAPP Hedge Fund Activity: Q2 2024 in Review
35 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q2 2024, worth a combined $593M.
Buyers outnumbered sellers: 35 funds opened new RAPP positions and 0 closed out — a net gain of 35 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $115M.
- 35 institutional investors held Rapport Therapeutics (RAPP) as of Q2 2024, up from 0 in Q1 2024.
- Funds reported $593M of Rapport Therapeutics stock for Q2 2024.
- 35 funds opened new Rapport Therapeutics positions in Q2 2024 and 0 closed out, a net change of +35 holders.
- The largest Rapport Therapeutics buyer in Q2 2024 was Fidelity Investments, an estimated $115M added.
Based on aggregated 13F filings for Q2 2024.